Literature DB >> 28850309

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Nasser Hanna1, David Johnson1, Sarah Temin1, Gregory Masters1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28850309     DOI： 10.1200/JOP.2017.026716

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  19 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

Authors:  Helen Adderley; Christoph Jakob Ackermann; Raffaele Califano
Journal:  Ann Transl Med       Date:  2019-12

3.  Body Weight Change in Non-small Cell Lung Cancer Patients Treated With EGFR-TKI.

Authors:  Takahide Kodama; Shinya Sato; Kunihiko Miyazaki; Shinichiro Okauchi; Yuika Sasatani; Gen Ohara; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Cancer Diagn Progn       Date:  2022-05-03

4.  Evaluation of the Cytotoxic Activity and Anti-Migratory Effect of Berberine-Phytantriol Liquid Crystalline Nanoparticle Formulation on Non-Small-Cell Lung Cancer In Vitro.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed G Almutary; Mohd Azam; Bikash Manandhar; Geena Hew Suet Yin; Lee Li Yen; Thiagarajan Madheswaran; Keshav Raj Paudel; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Pharmaceutics       Date:  2022-05-24       Impact factor: 6.525

5.  LncRNA HCG11 Suppresses Cell Proliferation and Promotes Apoptosis via Sponging miR-224-3p in Non-Small-Cell Lung Cancer Cells.

Authors:  Guige Wang; Lei Liu; Jiaqi Zhang; Cheng Huang; Yeye Chen; Wenliang Bai; Yanqing Wang; Ke Zhao; Shanqing Li
Journal:  Onco Targets Ther       Date:  2020-07-03       Impact factor: 4.147

6.  Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.

Authors:  Yu-Jin Wang; Qing-Wen Wang; Dong-Hu Yu; Cong-Kuan Song; Zi-Xin Guo; Xiao-Ping Liu; Chen Chen; Jie Yao; Ai-Fen Wang; Wei-Dong Hu
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-13       Impact factor: 4.553

Review 7.  Current clinical trials and patent update on lung cancer: a retrospective review.

Authors:  Harshul Batra; Shrikant Pawar; Dherya Bahl
Journal:  Lung Cancer Manag       Date:  2021-02-15

Review 8.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06

9.  LncRNA SENCR promotes cell proliferation and progression in non-small-cell lung cancer cells via sponging miR-1-3p.

Authors:  Ruirui Cheng; Guowei Zhang; Yong Bai; Furui Zhang; Guojun Zhang
Journal:  Cell Cycle       Date:  2021-07-05       Impact factor: 5.173

Review 10.  The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).

Authors:  Brandon Golding; Anita Luu; Robert Jones; Alicia M Viloria-Petit
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.